Fc-dependent expression of CD137 on human NK cells: Insights into "agonistic" effects of anti-CD137 monoclonal antibodies

Blood

Volumn 112, Issue 3, 2008, Pages 699-707

  Lin, Wei ^a   Voskens, Caroline J ^a   Zhang, Xiaoyu ^a   Schindler, Daniel G ^b   Wood, Aaron ^a   Burch, Erin ^a   Wei, Yadong ^c   Chen, Lieping ^d   Tian, Guoliang ^c   Tamada, Koji ^a   Wang, Lai Xi ^c   Schulze, Dan H ^a   Mann, Dean ^a   Strome, Scott E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b GTC Biotherapeutics Inc   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; FC RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; UNCLASSIFIED DRUG; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; CELL CULTURE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GLYCOSYLATION; METABOLISM; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; CELLS, CULTURED; GENE EXPRESSION REGULATION; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; KILLER CELLS, NATURAL; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS;

EID: 50949132226     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-122465     Document Type: Article

References (28)

1. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 2002;109:651-659.
2. Wilcox RA, Tamada K, Strome SE, Chen L. Signaling through NK cell-associated CD 137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol. 2002;169:4230-4236.
3. Melero I, Shuford W, Newby S, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3:682-685.
4. Martinet O, Ermekova V, Qiao JQ, et al. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J Natl Cancer Inst. 2000;92:931-936.
5. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106.
6. Melero I, Johnston J, Shufford W, Mittler R, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1-BB monoclonal antibodies. Cell Immunol. 1998;190:167-172.
7. Seo SK, Choi JH, Kim YH, et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med. 2004;10:1088-1094.
8. Foell J, Strahotin S, O'Neil SP, et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest. 2003;111:1505-1518.
9. Lee J, Lee E-N, Kim E-Y, et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Immunol Lett. 2005;101:210-216.
10. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibodycoated target cells. J Immunol Methods. 2005;304:88-99.
11. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fcgamma RI, Fcgamma RII, Fcgamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fcgamma R. J Biol Chem. 2001;276:6591-6604.
12. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibodydependent cellular toxicity. J Biol Chem. 2002;277:26733-26740.
13. Niwa R, Sakurada M, Kobayashi Y, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 2005;11:2327-2336.
14. Okazaki A, Shoji-Hosaka E, Nakamura K, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and Fc[gamma]RIIIa. J Mol Biol. 2004;336:1239-1249.
15. Nose M, Wigzell H. Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci U S A. 1983;80:6632-6636.
16. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG: role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 1989;143:2595-2601.
17. Weng W-K, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004;22:4717-4724.
18. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-3947.
19. Fischer L, Penack O, Gentilini C, et al. The antilymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol. 2006;34:753-759.
20. Pan P-Y, Gu P, Li Q, Xu D, Weber K, Chen S-H. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol. 2004;172:4779-4789.
21. Vinay DS, Choi BK, Bae JS, Kim WY, Gebhardt BM, Kwon BS. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J Immunol. 2004;173:4218-4229.
22. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633-640.
23. Kim KM, Kim HW, Kim JO, Baek KM, Kim JG, Kang CY. Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes. Immunology. 2002;107:472-479.
24. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106:376-383.
25. Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the Fcgamma RIIC gene. Blood. 1998;91:2369-2380.
26. Houtenbos I, Westers TM, Dijkhuis A, de Gruijl TD, Ossenkoppele GJ, van de Loosdrecht AA. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting. Clin Cancer Res. 2007;13:307-315.
27. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466-3473.
28. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65-78.